Revisiting the use of sPLA2‐sensitive liposomes in cancer therapy
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Controlled Release"
DOI: 10.1016/j.jconrel.2017.06.024
Abstract: Abstract The first developed secretory phospholipase A2 (sPLA2) sensitive liposomal cisplatin formulation (LiPlaCis®) is currently undergoing clinical evaluation. In the present study we revisit and evaluate critical preclinical parameters important for the therapeutic potential and… read more here.
Keywords: spla2 sensitive; use spla2; revisiting use; cancer ... See more keywords